In 2007, biotechnology company Seagen Inc. and pharmaceutical company Astellas Pharma Inc. (“Astellas”) collaborated to develop enfortumab vedotin. Now, in 2021, the pair submitted two
The Cystic Fibrosis Foundation is dedicated to finding a cure for the rare, genetic disorder. They fund more CF research than any other organization, and
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on
According to a story from One News Page, the biopharmaceutical company BridgeBio Pharma and its affiliate ML Bio Solutions have recently announced that dosing has
The FDA has recently accepted NeoImmuneTech’s Investigational New Drug (IND) application for NT-17, a treatment for progressive multifocal leukoencephalopathy (PML). Now that the application has
During clinical development, treatments are sometimes first evaluated in healthy volunteers. This is the route that Insmed Incorporated (“Insmed”) took with treprostinil palmitil inhalation powder
© Copyright Patient Worthy
